luseogliflozin

Luseogliflozin is an orally active, second-generation small molecule inhibitor of sodium-glucose co-transporter 2 (SGLT2), developed for the treatment of type 2 diabetes mellitus. By selectively inhibiting SGLT2 in the renal proximal tubules, it reduces glucose reabsorption and promotes urinary glucose excretion, thereby lowering plasma glucose levels. Clinical studies have shown that it improves glycemic control and also provides additional metabolic benefits such as reductions in body weight, blood pressure, serum triglycerides, uric acid, and liver enzymes. Luseogliflozin was first approved in Japan in 2014 and is marketed under the brand name Lusefi[1][2][3][4][5].

Brand names

Lusefi

Other names

luseogliflozin hydratelusefiluseogliflozinaluseogliflozineluseogliflozinum